Starling Oncology, Inc. STLN
$6.90
$0.274.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 38.38% | 35.37% | 27.79% | 21.67% | 17.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.38% | 35.37% | 27.79% | 21.67% | 17.53% |
| Cost of Revenue | 37.28% | 34.72% | 25.60% | 20.77% | 17.96% |
| Gross Profit | 44.57% | 39.18% | 41.55% | 27.10% | 15.18% |
| SG&A Expenses | 7.38% | 3.49% | -2.09% | -7.90% | -7.90% |
| Depreciation & Amortization | -0.87% | 2.95% | 10.45% | 14.00% | 9.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.14% | 27.07% | 18.80% | 13.47% | 10.97% |
| Operating Income | 44.38% | 37.21% | 39.98% | 35.36% | 26.27% |
| Income Before Tax | 45.03% | 32.19% | 6.07% | 5.87% | 7.95% |
| Income Tax Expenses | 100.00% | -- | -- | 58.28% | 26.82% |
| Earnings from Continuing Operations | 44.92% | 32.39% | 6.27% | 5.63% | 7.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.92% | 32.39% | 6.27% | 5.63% | 7.90% |
| EBIT | 44.38% | 37.21% | 39.98% | 35.36% | 26.27% |
| EBITDA | 51.84% | 43.03% | 45.87% | 40.65% | 30.18% |
| EPS Basic | 54.91% | 46.10% | 20.34% | 16.71% | 14.45% |
| Normalized Basic EPS | 53.57% | 43.84% | 26.49% | 22.63% | 19.84% |
| EPS Diluted | 55.40% | 46.74% | 21.05% | 17.11% | 13.73% |
| Normalized Diluted EPS | 53.57% | 43.84% | 26.49% | 22.63% | 19.84% |
| Average Basic Shares Outstanding | 25.59% | 30.00% | 23.01% | 15.25% | 8.64% |
| Average Diluted Shares Outstanding | 25.59% | 30.00% | 23.01% | 15.25% | 8.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |